BioMarin Pharmaceuticals BMRN Unrealized Losses on Investments (Before Tax)
Unrealized Losses on Investments (Before Tax) at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's unrealized losses on investments (before tax).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's unrealized losses on investments (before tax)?
- BioMarin Pharmaceuticals (BMRN) reported unrealized losses on investments (before tax) of $0 in Q1 2026.
- How has BioMarin Pharmaceuticals's unrealized losses on investments (before tax) changed year-over-year?
- BioMarin Pharmaceuticals's unrealized losses on investments (before tax) decreased by 100.0% year-over-year, from $245K to $0.
- What is the long-term trend for BioMarin Pharmaceuticals's unrealized losses on investments (before tax)?
- Over 5 years (2020 to 2025), BioMarin Pharmaceuticals's unrealized losses on investments (before tax) has grown at a -6.2% compound annual growth rate (CAGR), from $11K to $8K.